According to Coherent Market Insights, the global adoptive cell therapy market size is estimated to be valued at USD 4,932.5 million in 2022 and is expected to surpass USD 23,440.7 million by 2030, growing at a CAGR of 21.5% from 2023 to 2030.
The growth of the adoptive cell therapy market is attributed to rising incidence of cancer globally and increasing adoption of cell-based cancer immunotherapy. According to the World Health Organization (WHO), cancer is the second leading cause of death globally, and was responsible for nearly 10 million deaths in 2020.
Request a Sample Copy of the Report @ https://www.coherentmarketinsights.com/insight/request-sample/4957
Furthermore, growing research in CAR T-cell therapy for applications other than hematologic cancers is also a major factor driving market growth. For instance, in January 2022, researchers from Memorial Sloan Kettering Cancer Center published results of a Phase 1 clinical trial studying the safety and efficacy of CAR T cells targeting mesothelin antigen in treating advanced solid tumors.
Market Trends:
Increasing research for development of CAR-T therapies for solid tumors represents a key trend in the adoptive cell therapy market. Traditionally, CAR T-cell therapies have focused on hematological cancers. However, companies are now directing efforts towards developing these therapies against various solid tumors. For example, in January 2022, Celyad Oncology announced data from phase 1b KEYNOTE-B79 clinical trial of CYAD-101 for metastatic colorectal cancer.
Adoptive Cell Therapy Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2022 |
$4,932.5 million |
|
Estimated Value by 2030 |
$23,440.7 million |
|
Growth Rate |
Poised to grow at a CAGR of 21.5% |
|
Historical Data |
2017–2020 |
|
Forecast Period |
2022–2030 |
|
Forecast Units |
Value (USD Million/Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
By Type, By Application, By End User |
|
Geographies Covered |
North America, Europe, Asia Pacific, and Rest of World |
|
Growth Drivers |
• Increasing research and development for adoptive cell therapy • Rising prevalence of cancer • Increasing product approvals |
|
Restraints & Challenges |
• Side effect associated with adoptive cell therapy |
The trial results demonstrated that CYAD-101 can be administered safely and induce anti-tumor activity in patients with mCRC. Rising number of ongoing clinical trials evaluating CAR T-cell therapies for various solid tumors such as ovarian cancer, brain cancer, and lung cancer is expected to drive the market growth over the forecast period.
Market Opportunities:
Cancer remains one of the leading causes of death worldwide. According to the WHO, cancer burden is expected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths by 2040. The rising incidence of various cancers such as blood cancer, lung cancer, breast cancer, and prostate cancer is expected to drive the demand for adoptive cell therapy during the forecast period.
Immediate Delivery Available | Buy This Premium Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4957
Major players in the adoptive cell therapy market are focusing on developing next-generation cell therapies through increased investments in R&D. For instance, Novartis invested over US$ 700 million to develop Kymriah, the first FDA-approved CAR-T cell therapy drug. In addition, various government organizations and private foundations are also funding research on cell therapies.
Key Market Takeaways
The global adoptive cell therapy market is anticipated to witness a CAGR of 21.5% during the forecast period 2022-2030, owing to the rising prevalence of cancer worldwide.
On the basis of target antigen, CD19 segment is expected to hold a dominant position, accounted for over 30% market share in 2022 due to high success rates of CD19 CAR T-cell therapies in blood cancer.
By application, diffuse large B-cell lymphoma segment is expected to dominate the market, owing to large patient pool and presence of approved CAR T-cell therapies for this indication.
On the basis of region, North America is expected to hold a dominant position over the forecast period. This is due to presence of advanced healthcare infrastructure and FDA approval of major CAR T-cell therapies in the U.S.
Competitor Insights
- Bluebird Bio
- Intellia Therapeutics
- Noile-Immune Biotech
- Celgene Corporation
- Bellicum Pharmaceuticals, Inc.
- Novartis International AG
- Celyad
Recent Development:
In October 2023, The Central Drugs Standard Control Organization, India's equivalent of the U.S. Food and Drug Administration, authorized NexCAR19 as the country's first CAR-T cell therapy.
Ask For Customization @ https://www.coherentmarketinsights.com/insight/request-customization/4957
Detailed Segmentation:
By Type:
- CAR-T
- TCR-T
- NK
- TIL
By Application:
- Lymphoma
- Leukemia
- Others
By End User:
- Hospitals
- Cancer Treatment Centers
By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Find Most Trending Related Reports:
Global CAR
T cell therapy market is estimated
to be valued at US$ 2.26 Billion in 2022 and is expected to exhibit a CAGR of
20.9 % during the forecast period (2022-2030).
The PD-1
and PD-L1 inhibitor market is
estimated to be valued at USD 52.51 Bn in 2024 and is expected to reach USD
170.01 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 18.3%
from 2024 to 2031.
The global immune
checkpoint inhibitors market is estimated to be valued at US$ 1,444.7 million in 2022 and is
expected to exhibit a CAGR of 13.2% during the forecast period (2022-2030).
The global T-cell lymphoma market is estimated to be valued at US$ 1,627.1 million in 2021 and is expected to exhibit a CAGR of 9.8% over the forecast period (2021-2028).
The Global Compounding Chemotherapy Market size was valued at US$ 5.29 Bn in 2023 and is projected to reach US$ 7.41 Bn by 2030, growing at a CAGR of 4.9% from 2023 to 2030.
About Us:
Coherent Market Insights is a global market intelligence and consulting
organization that provides syndicated research reports, customized research
reports, and consulting services. We are known for our actionable insights and
authentic reports in various domains including aerospace and defense,
agriculture, food and beverages, automotive, chemicals and materials, and
virtually all domains and an exhaustive list of sub-domains under the sun. We
create value for clients through our highly reliable and accurate reports. We
are also committed in playing a leading role in offering insights in various
sectors post-COVID-19 and continue to deliver measurable, sustainable results
for our clients.
Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-650-918-5898
UK: +44-020-8133-4027
AUS: +61-2-4786-0457
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
